, Volume 9, Issue 1–3, pp 87–90 | Cite as

Lessons from a pilot study of transfer factor in chronic fatigue syndrome

  • Caterina De Vinci
  • Paul H. Levine
  • Giancarlo Pizza
  • Hugh H. Fudenberg
  • Perry Orens
  • Gary Pearson
  • Dimitri Viza


Transfer Factor (TF) was used in a placebo controlled pilot study of 20 patients with chronic fatigue syndrome (CFS). Efficacy of the treatment was evaluated by clinical monitoring and testing for antibodies to Epstein-Barr virus (EBV) and human herpes virus-6 (HHV-6). Of the 20 patients in the placebo-controlled trial, improvement was observed in 12 patients, generally within 3-6 weeks of beginning treatment. Herpes virus serology seldom correlated with clinical response. This study provided experience with oral TF, useful in designing a larger placebo-controlled clinical trial.

Key words

CMV chronic fatigue syndrome EBV herpes viruses HHV-6 transfer factor 



chronic fatigue syndrome




Epstein-Barr virus


EBV-early antigens


EBV-Viral capsid antigen


human herpes virus-6


Herpes simplex virus


transfer factor


non-specific transfer factor




Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG & Komaroff A. International Chronic Fatigue Syndrome Study Group. The Chronic fatigue syndrome: a comprehensive approach to its definition. Ann Int Med 1994; 121: 953–9.PubMedGoogle Scholar
  2. 2.
    Nkrumah F, Pizza G, Viza D, Phillips J, De Vinci C & Levine PH. Regression of progressive lymphadenopathy in a young child with acute cytomegalovirus (CMV) infection following the administration of transfer factor with specific anti-CMV activity. Lymphokine Res 1985; 4: 237–41.PubMedGoogle Scholar
  3. 3.
    Neequaye J, Viza D, Pizza D, Levine PH, De Vinci C, Ablashi DV, Biggar RJ & Nkrumah FK. Specific transfer factor with activity against Epstein-Barr virus reduces late relapse in endemic Burkitt’s lymphoma. Anticanc R 1990; 10: 1183–1187.Google Scholar
  4. 4.
    Viza D, Vich JM, Phillips J & Rosenfeld F. Orally administered specific transfer factor for the treatment of herpes infections. Lymphokine Res 1985; 4: 27–30.PubMedGoogle Scholar
  5. 5.
    Rosenfeld F, Viza D, Phillips J, Vich JM, Binet O & Aron-Brunetière R. Traitement des infections herpétiques par le facteur de transfert. Presse Méd 1984; 13: 537–540.PubMedGoogle Scholar
  6. 6.
    Meduri R, Campos E, Scorolli L, De Vinci C, Pizza G & Viza D. Transfer Factor in recurrent ocular herpes. Biotherapy, this issue.Google Scholar
  7. 7.
    Pizza G, Viza D, De Vinci C, Palareti A, Cuzzocrea D, Fornarola F & Baricordi OR. Orally administered HSV-specific Transfer Factor (TF) prevents genital and/or labial herpes relapses. Biotherapy, this issue.Google Scholar
  8. 8.
    Viza D, Vich JM, Phillips J, Rosenfeld F & Davies DAL. Specific transfer factor protects mice against lethal challenge with herpes simplex virus. Cell Immun 1986; 100: 555–562.CrossRefGoogle Scholar
  9. 9.
    Buchwald D, Cheney PR, Peterson DL, Henry B, Wormsley SB, Geiger A, Ablashi DV, Salahuddin SZ, Saxinger C, Biddle R, Kilkinis R, Jolesz FA, Folks T, Balachandran N, Gallo RD & Komaroff AL. A chronic illness characterized by fatigue, neuralgia, and immunologic disorders and active herpesvirus-6 type infection. Ann Int Med 1992; 116: 103–113.PubMedGoogle Scholar
  10. 10.
    Pizza G, Viza D, Ablashi DV, Jerome L, Armstrong G & Levine PH. The possible use of specific transfer factor in the treatment of patients with nasopharyngeal carcinoma. In: Grundman E, Krueger GRF, Ablashi DV eds, Nasopharyngeal Carcinoma. Stuttgart: Gustav Fisher-Verlag Editor, 1981, 301–307.Google Scholar
  11. 11.
    Viza D, Goust JM, Moulias R, Trejdosiewicz LK, Collard A & Mueller-Berat N. ‘In vitro’ production of transfer factor by lymphoblastoid cell lines. Transplan P 1975; VII (suppl. 1): 329–333.Google Scholar
  12. 12.
    Ablashi DV, Levine PH, Kaplan M, DeVinci C, Whitman JE, Pizza G & Viza D. In Vivo Effectiveness of anti HHV-6 transfer factor in two patients with chronic fatigue syndrome (CFS) Biotherapy, this issue.Google Scholar
  13. 13.
    Levine PH: The use of transfer factors in chronic fatigue syndrome: prospects and problems. Biotherapy, this issue.Google Scholar
  14. 14.
    Straus SE, Dale JK, Tobi M, et al. Acyclovir treatment of the chronic fatigue syndrome: lack of efficacy in a placebocontrolled trial. N Eng J Med 1988; 319: 1692–98.CrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Caterina De Vinci
    • 5
  • Paul H. Levine
    • 1
  • Giancarlo Pizza
    • 5
  • Hugh H. Fudenberg
    • 2
  • Perry Orens
    • 3
  • Gary Pearson
    • 1
  • Dimitri Viza
    • 4
  1. 1.Georgetown UniversityWashington DCUSA
  2. 2.NeuroImmuno Therapeutics FoundationSpartanburgUSA
  3. 3.Great NeckNew YorkUSA
  4. 4.Laboratoire d’Immunobiologie, URA 1294 CNRSFaculté de MédecineParisFrance
  5. 5.Immunodiagnosis and Immunotherapy Unit, 1st Division of UrologySant’ Orsola-Malpighi HospitalBolognaItaly

Personalised recommendations